Retension Pharmaceuticals

🗓 Founded 2023👥 10 employees💰 Last funded Jun 2025
Biotechnology Research🌐 retensionpharmaceuticals.com
Website LinkedIn
Retension Pharmaceuticals is developing RTN-001, a differentiated, tissue-targeted PDE5 inhibitor that has been optimized for the treatment of uncontrolled hypertension. RTN-001 has been evaluated in over 265 subjects across 9 clinical trials. In these studies, RTN-001 was well tolerated and demonstrated a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension. RTN-001 is a second generation PDE5i that preferentially distributes to cardiovascular tissues, where it acts to mediate a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2023
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Retension Pharmaceuticals?
Retension Pharmaceuticals has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Retension Pharmaceuticals last raise funding?
The most recent investment in Retension Pharmaceuticals recorded on gritt.io was in June 2025.
When was Retension Pharmaceuticals founded?
Retension Pharmaceuticals was founded in 2023.
What industry is Retension Pharmaceuticals in?
Retension Pharmaceuticals operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.